Search results
Diabetic ketoacidosis (DKA) is a frequent and potentially life-threatening complication of type 1 diabetes. Though preventable and despite advances in monitoring technologies, insulin therapeutics and insulin delivery systems, the rates of both community and hospital acquired DKA remain largely unchanged. Although mortality today is relatively
22 maj 2020 · MONTEFIORE SUBCUTANEOUS INSULIN DKA PROTOCOL. This is a subcutaneous (SubQ) insulin protocol that replaces insulin drip needs for mild to moderate DKA. Procedures are adapted for COVID-related considerations of minimizing risk to staff while optimizing patient safety and health.
DIABETIC KETOACIDOSIS – INITIAL MANAGEMENT GUIDE. DIAGNOSIS OF DKA BLOOD GLUCOSE(BG) > 11*- (glucose may be normal in a known diabetic) + ACIDOSIS - pH <7.3 or HCO3-<15mmol/l + KETONAEMIA – Bld Ketones> 3mmol/l.
Starting the Insulin Drip . If patient is in DKA: Weight of patient in KG __________ X 0.1 units= __________ units/hour . Directions. Check blood glucose every hour and adjust according to the table provided below. Multiply current infusion rate by number provided in table. The result is your new insulin drip rate.
*The BCCH DKA Medical Protocol can also be downloaded in fillable PDF format from our website: www.bcchildrens.ca/endocrinology-diabetes-site/documents/dkaprtfill.pdf.
UNIVERSITY OF WASHINGTON SUBCUTANEOUS INSULIN DKA PROTOCOL. This is a subcutaneous (SC) insulin protocol that replaces the IV insulin infusion needs for mild to moderate DKA, adapted to minimize the risks to staff exposure, use of PPE, while optimizing patient safety.
ada-montefiore_dka_protcol_version_3.0_5_22_20 - Free download as PDF File (.pdf), Text File (.txt) or read online for free. This document presents a subcutaneous insulin protocol for treating mild to moderate diabetic ketoacidosis (DKA) developed by Montefiore hospital.
